Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors.

Clinical Cardiology
Katrien BlanchartFarzin Beygui

Abstract

We sought to investigate the safety and potential benefit of administrating glycoprotein IIb-IIIa inhibitors (GPIs) on top of more potent P2Y12 inhibitors. A number of clinical trials, performed at a time when pretreatment and potent platelet inhibition was not part of routine clinical practice, have documented clinical benefits of GPI in ST-segment elevation myocardial infarction (STEMI) patients at the cost of a higher risk of bleeding. We used the data of a prospective, ongoing registry of patients admitted for STEMI in our center. For the purpose of this study only patients presenting for primary percutaneous coronary intervention and pretreated with new P2Y12 inhibitors (prasugrel or ticagrelor) were included. We compared patients who received GPI with those who did not. Eight hundred twenty-four STEMI patients were included in our registry; GPIs were used in 338 patients (41%). GPI patients presented more often with cardiogenic shock and Thrombolysis in myocardial infarction (TIMI) flow grade <3. GPI use was not associated with an increase in in-hospital or 3-month mortality. Bleeding endpoints were similar in both groups. Our study suggests that GPI may be used safely in combination with recent P2Y12 inhibitors in STEMI ...Continue Reading

References

Jun 23, 2001·The New England Journal of Medicine·G MontalescotUNKNOWN ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Te
Mar 29, 2002·The New England Journal of Medicine·Gregg W StoneUNKNOWN Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators
Oct 29, 2003·Archives of Internal Medicine·Christopher B GrangerUNKNOWN Global Registry of Acute Coronary Events Investigators
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Sep 10, 2013·The American Journal of Cardiology·Jean-Philippe ColletUNKNOWN ATOLL Investigators
Sep 2, 2014·The New England Journal of Medicine·Gilles MontalescotUNKNOWN ATLANTIC Investigators
Aug 31, 2018·European Heart Journal·Franz-Josef NeumannUNKNOWN ESC Scientific Document Group
Aug 31, 2018·European Heart Journal·Kristian ThygesenUNKNOWN ESC Scientific Document Group
Sep 24, 2018·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Homam IbrahimTracy Y Wang
Nov 22, 2019·Thrombosis and Haemostasis·Anne H TavenierUNKNOWN ATLANTIC investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.